ENXTPA:ABVXBiotechs
Is Obefazimod’s Phase 3 UC Success Reshaping The Investment Case For ABIVAX (ENXTPA:ABVX)?
Abivax, a France-based clinical-stage biotech, previously reported that its lead candidate obefazimod achieved statistically significant remission rates in phase 3 trials for moderate to severe ulcerative colitis, including patients with inadequate responses to prior therapies.
The company now plans a U.S. regulatory submission for obefazimod in the second half of 2026, potentially opening the door to additional inflammatory bowel disease indications such as Crohn’s disease.
We’ll explore...